Trials / Not Yet Recruiting
Not Yet RecruitingNCT06210438
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases：a Prospective, Single-arm, Single-center Phase II Clinical Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1921 + Bevacizumab | SHR-A1921 + Bevacizumab |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2025-06-30
- Completion
- 2026-06-30
- First posted
- 2024-01-18
- Last updated
- 2024-01-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06210438. Inclusion in this directory is not an endorsement.